Valuation: BriaCell Therapeutics Corp.

Market Cap 2.99Cr 2.68Cr 2.47Cr 2.24Cr 4.18Cr 284.64Cr 4.25Cr 29Cr 12Cr 148.97Cr 11Cr 11Cr 471.82Cr P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 1.2Cr 1.08Cr 99.36L 89.92L 1.68Cr 114.51Cr 1.71Cr 12Cr 4.73Cr 60Cr 4.51Cr 4.42Cr 189.81Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
29/10 BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2026 CI
23/10 Briacell Therapeutics Corp. Announces Clinical Biomarker Findings from Prospective Pooled Analysis of Patients with Metastatic Breast Cancer Treated with Immune Based Therapies Including the Briacell Regimen CI
14/09 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
11/09 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
08/09 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
02/09 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
02/09 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
24/08 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
06/08 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
05/08 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
1 day-1.85%
1 week-1.45%
Current month-21.80%
1 month-17.76%
3 months-1.24%
6 months-13.27%
Current year-51.33%
1 week 4.72
Extreme 4.72
5.1
1 month 4.72
Extreme 4.72
6.15
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
18
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 01/11/2016
Director of Finance/CFO 54 01/02/2016
Chief Tech/Sci/R&D Officer 65 16/02/2022
Director TitleAgeSince
Director/Board Member 70 01/11/2016
Chairman 41 24/04/2019
Director/Board Member 74 07/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%-1.45%-72.59%-99.43% 3.01Cr
+0.34%-3.03%+37.45%+61.06% 6.41TCr
+0.98%+2.68%+12.25%+83.90% 5.55TCr
+1.75%+2.01%+13.30%+105.71% 5.3TCr
-1.70%-1.14%+26.31%+55.31% 4.6TCr
-1.10%-3.14%+17.61%+98.42% 4.25TCr
-0.46%+0.40%+224.78%+926.92% 4.04TCr
-0.26%-4.20%+10.86%+45.18% 3.23TCr
-2.07%+42.73%+103.77%+90.26% 3.45TCr
-2.72%-8.79%+22.58%-5.63% 2.42TCr
Average -0.74%+3.01%+39.63%+136.17% 3.93TCr
Weighted average by Cap. -0.35%+3.13%+49.19%+160.04%

Financials

2024 2025
Net sales - -
Net income -47.91L -42.92L -39.59L -35.83L -67L -46Cr -68.08L -4.72Cr -1.88Cr -24Cr -1.8Cr -1.76Cr -76Cr -2.63Cr -2.36Cr -2.17Cr -1.97Cr -3.68Cr -250.56Cr -3.74Cr -26Cr -10Cr -131.13Cr -9.87Cr -9.66Cr -415.33Cr
Net Debt -9L -8L -7L -6L -12.05L -8.21Cr -12.25L -84.99L -33.91L -4.3Cr -32.35L -31.66L -14Cr -1.79Cr -1.6Cr -1.48Cr -1.34Cr -2.5Cr -170.14Cr -2.54Cr -18Cr -7.03Cr -89Cr -6.71Cr -6.56Cr -282.02Cr
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
29/26/29 CA$4.770 -1.85% 1,411
28/26/28 CA$4.860 -2.99% 2,012
27/26/27 CA$5.010 +2.87% 4,150
26/26/26 CA$4.870 +1.67% 4,182
23/26/23 CA$4.790 -1.03% 1,187

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.